VRAI-CURE Virtual Reality and AI for Real-Time Clinical Decision Support and Intracranial Aneurysm Risk Prediction
- Coordinator
- Association Pour La Recherche Et Le Developpement Des Methodes Et Processus Industriels, France
- Runs
- 1 January 2026 to 30 June 2027
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 2 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101247532
What the project is doing
In the project's own words, from its summary on CORDIS.
Intracranial aneurysms (IAs) pose a severe neurovascular threat, with rupture leading toIntracranial aneurysms (IAs) pose a severe neurovascular threat, with rupture leading to life-threatening complications. Current treatment planning relies on static imaging and computational fluid dynamics, which are computationally expensive and lack real-time clinical integration. Clinicians face uncertainty in selecting optimal intervention strategies, increasing procedural risks and costs.
VRAI-CURE proposes an AI-driven clinical decision support system that combines Physics-Constrained Graph Neural Networks for real-time hemodynamic simulation and immersive Virtual Reality (VR) visualization. This system enables instantaneous, patient-specific blood flow predictions, transforming clinical workflows by providing neurovascular specialists with actionable insights for treatment planning. Unlike conventional simulation or imaging methods, the proposed AI-based approach is computationally efficient, self-improving with each new patient case, and seamlessly integrates into standard imaging workflows (MRI, CT, angiography).
By delivering an interactive VR-based visualization of blood flow dynamics, VRAI-CURE enhances clinical understanding of aneurysm behavior and treatment effects, facilitating personalized decision-making. Our preliminary validation demonstrates superior accuracy and efficiency compared to existing techniques, addressing a significant gap in neurovascular intervention. With the VR healthcare market projected to reach $40 billion by 2032, the transformative potential extends beyond neurovascular medicine, offering a cutting-edge solution in a rapidly expanding sector.
This project aims to advance to TRL 6, developing a certified clinical prototype ready for industrial transfer. The project’s high-risk/high-gain potential positions it as a transformative innovation in precision neurovascular medicine, with broad implications for AI-driven clinical decision support.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Association Pour La Recherche Et Le Developpement Des Methodes Et Processus Industriels | Paris | France | Coordinator |
| Ecole Nationale Superieure Des Mines De Paris | Paris | France | Third party |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI